Abalos Therapeutics Raises €32.5M in Series A Extension - FinSMEs

Oct 15, 2021 · Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in …

CouponFollow Extension

€32
OFF

Abalos Therapeutics Raises €32.5M In Series A Extension - FinSMEs

1 week from now

Oct 15, 2021 · Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in …

finsmes.com

€10
OFF

Abalos Therapeutics GmbH. (10/14/21). "Press Release: Abalos ...

1 week from now

Sequentia Biotech Raises €10m Series A Led by Seventure; Evotec & Novo Nordisk: Cell Therapy Tech Development ... (10/14/21). "Press Release: Abalos Therapeutics Completes …

life-sciences-europe.com

$38
OFF

Abalos Adds $38M In Series A Extension To Take Virotherapy

1 week from now

Oct 14, 2021 · DUBLIN – Abalos Therapeutics GmbH raised €32.5 million (US$37.6 million) in a series A extension, taking the total raise to €43 million, enough to enable the company to …

bioworld.com

$13240195
OFF

Series A - Abalos Therapeutics - 2019-10-15 - Crunchbase

1 week from now

Oct 15, 2019 · Abalos Therapeutics raised $13240195 on 2019-10-15 in Series A

crunchbase.com

$50
OFF

Abalos Therapeutics Scores $50m Series A Extension

1 week from now

Oct 14, 2021 · Düsseldorf, Germany, October 14, 2021 – Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 …

venturecapitaljournal.com

$126
OFF

Halda Therapeutics Raises $126M In Series B Extension Financing

1 week from now

Aug 12, 2024 · Halda Therapeutic s, a New Haven, CT-based biotechnology company developing a novel class of cancer therapies called RIPTAC TM (Regulated Induced Proximity TArgeting …

finsmes.com

$20
OFF

Aulos Bioscience Raises $20M In Series A Extension Financing

1 week from now

Aug 1, 2023 · Aulos Bioscience, a Larkspur, CA-based immuno-oncology company, raised $20m in Series A extension funding. Apple Tree Partners (ATP) made the investment. The company …

finsmes.com

$92
OFF

SynOx Therapeutics Raises Additional Funding In Series B Round; …

1 week from now

Oct 30, 2024 · The round, which brought the total amount to $92M, was led by Gilde Healthcare with participation from Forbion, HealthCap and Bioqube Ventures.

finsmes.com

$225
OFF

Seaport Therapeutics Closes $225M Series B Financing Round

1 week from now

Oct 21, 2024 · Seaport Therapeutics, a Boston, MA-based biopharmaceutical company that is developing novel neuropsychiatric medicines, raised $225M in Series B funding.

finsmes.com

$50
OFF

Iambic Therapeutics Raises $50M In Series B Extension Funding

1 week from now

Jun 19, 2024 · Iambic Therapeutics, a San Diego, CA-based clinical-stage biotechnology company, raised $50M in Series B extension funding.

finsmes.com

FAQs about Abalos Therapeutics Raises €32.5M in Series A Extension - FinSMEs Coupon?

How much money did Abalos Therapeutics raise?

DÜSSELDORF, Germany-- ( BUSINESS WIRE )-- Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 million (USD 50 million). ...

What is Abalos Therapeutics?

About Abalos Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. ...

What is Abalos Therapeutics' new anti-cancer approach?

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. ...

How does Abalos work?

Through its proprietary Fast Evolution Platform, Abalos is generating variants with optimized anti-tumoral properties to trigger a highly precise and directed immune response that can be utilized for distant metastases and enable long-term disease control. ...

What is Abalos technology?

Abalos was launched in October 2019 to advance a technology platform that harnesses the unique features of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. ...

Who will join Abalos' supervisory board?

In conjunction with the closing of the Series A financing round extension, Annegret de Baey from Seventure Partners and Sebastian Pünzeler from Coparion will join Abalos’ Supervisory Board. ...